---
schema_version: "secwatch.filing_event.v1"
accession: "0001093557-24-000179"
form_type: "8-K"
ticker: "DXCM"
cik: "0001093557"
company_name: "DEXCOM INC"
filed_at: "2024-10-24T23:59:59+00:00"
generated_at: "2026-05-30T10:20:02.270870+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Dexcom Q3 revenue $994M (+2%); reiterates FY24 guidance; CCO retiring

## Summary
- Revenue $994.2M (+2% reported, +3% organic); U.S. down 2%, international up 12%.
- GAAP net income $134.6M ($0.34 EPS); Non-GAAP $179.9M ($0.45 EPS). Operating margin contracted.
- Launched Stelo OTC glucose biosensor in U.S.; Dexcom G7 in Australia, ONE+ in France.
- FY24 guidance reaffirmed: revenue ~$4.00-4.05B, non-GAAP operating margin ~20%.
- Teri Lawver, EVP & Chief Commercial Officer, retiring year-end; CEO Sayer leading commercial while search ongoing.

## SEC filing metadata
- accession: 0001093557-24-000179
- form_type: 8-K
- ticker: DXCM
- cik: 0001093557
- company_name: DEXCOM INC
- filed_at: 2024-10-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1093557/000109355724000179/0001093557-24-000179-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1093557/000109355724000179/dxcm-20241024.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001093557-24-000179
- JSON: https://secwatch.observer/filing/0001093557-24-000179.json
- Plain text: https://secwatch.observer/filing/0001093557-24-000179.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.